What are the indications and dosing recommendations for tranexamic acid in adults and children?

Tranexamic Acid: Indications and Dosing

Tranexamic acid should be administered to trauma patients who are bleeding or at risk of significant hemorrhage at 1 g IV over 10 minutes, followed by 1 g IV over 8 hours, given as early as possible and within 3 hours of injury. 1, 2, 3

Primary Indication: Trauma with Active or Risk of Significant Bleeding

Adults - Trauma Setting

Dosing regimen:

• Loading dose: 1 g IV infused over 10 minutes
• Maintenance dose: 1 g IV infused over 8 hours
• Critical timing: Must be administered within 3 hours of injury 1, 3

Key evidence points:

• The CRASH-2 trial (n=20,211) demonstrated mortality reduction from 16.0% to 14.5% (RR 0.91,95% CI 0.85-0.97) when TXA was given early 1, 2
• Death from bleeding specifically decreased by one-third 1
• Every 15-minute delay reduces benefit by 10% 4
• Administration beyond 3 hours shows no benefit and may increase risk of death from hemorrhage (RR 1.44,95% CI 1.12-1.84) 1

Clinical criteria for administration:

• Systolic blood pressure <90 mmHg, OR
• Heart rate >110 bpm, OR
• Clinical judgment of significant bleeding risk 1

Important: Do not restrict TXA to only the most severely injured—benefit is consistent across varying probabilities of death 1

Pediatric Trauma Dosing

Recommended dosing based on pharmacokinetic modeling:

• Loading dose: 25 mg/kg IV bolus (maximum 2 g) 5
• Alternative range studied: 10-30 mg/kg loading dose followed by 5-10 mg/kg/h maintenance infusion 6

The 25 mg/kg dose approximates adult Cmax achieved with 2 g bolus, though more frequent dosing may be needed to match total drug exposure 5. Pediatric-specific guidelines remain inconsistent, but evidence supports efficacy in reducing blood loss and transfusion requirements 7, 8.

Traumatic Brain Injury

Dosing: Same as general trauma (1 g over 10 min, then 1 g over 8 h) within 3 hours of injury 1

The CRASH-3 trial (n=12,737) showed:

• Reduced head injury-related death in mild-to-moderate TBI (RR 0.78,95% CI 0.64-0.95) when given within 3 hours 3
• No benefit in severe TBI (RR 0.99,95% CI 0.91-1.7) 3
• May reduce progression of intracranial bleeding 9

Do not use in non-traumatic intracranial hemorrhage—the TICH-NOAC study found no efficacy 10

Postpartum Hemorrhage

Dosing regimen: 4

• First dose: 1 g IV at 1 mL/min (over 10 minutes)
• Second dose: 1 g IV if bleeding continues after 30 minutes OR restarts within 24 hours
• Timing: Within 3 hours of birth

Indications:

• Blood loss >500 mL after vaginal birth, OR
• Blood loss >1000 mL after cesarean section, OR
• Any blood loss compromising hemodynamic stability

Critical update: The 2017 WHO guideline now recommends TXA for ALL cases of postpartum hemorrhage, regardless of cause (uterine atony, trauma, etc.), not just when uterotonics fail 4

Bleeding in Anticoagulated Patients

TXA should be administered according to the same indications as non-anticoagulated patients 10

Rationale: TXA and anticoagulants act on different targets. Evidence supports use in:

• Epistaxis (reduces 10-day recurrence risk) 10
• Gingival/oral bleeding (topical or mouthwash) 10
• Metrorrhagia (oral administration) 10

Do NOT use for upper GI hemorrhage (HALT-IT study showed no benefit) 10

FDA-Approved Indication: Hemophilia

Dosing for tooth extraction: 11

• Before extraction: 10 mg/kg IV single dose immediately before procedure
• After extraction: 10 mg/kg IV 3-4 times daily for 2-8 days
• Infusion rate: No more than 1 mL/minute to avoid hypotension

Dose Adjustments for Renal Impairment

Adults: 11

• Serum creatinine 1.36-2.83 mg/dL: 10 mg/kg twice daily
• Serum creatinine 2.83-5.66 mg/dL: 10 mg/kg once daily
• Serum creatinine >5.66 mg/dL: 10 mg/kg every 48 hours OR 5 mg/kg every 24 hours

For major joint arthroplasty in chronic kidney disease, consider bolus of 15 mg/kg over 15 min with maintenance infusion of 5 mg/kg/h for 2 hours in poor renal function 12

Other Surgical Applications

General surgery: Evidence supports prophylactic use to reduce bleeding and transfusion requirements 13. Despite NICE guidelines since 2016, approximately 25% of eligible UK surgical patients do not receive TXA 13

Cardiac surgery: Effective but avoid high doses (>4 g) due to seizure risk 2

Critical Safety Considerations

Contraindications 11

• Subarachnoid hemorrhage (risk of cerebral edema/infarction)
• Active intravascular clotting
• Hypersensitivity to TXA

Thromboembolic Risk

• Dose-dependent, with marked increase at 4 g (HR 5.33,95% CI 1.94-14.63) 9
• Avoid concomitant use with prothrombotic agents (Factor IX concentrates, hormonal contraceptives) 11
• CRASH-2 and PATCH trials showed no increased thrombotic events with standard dosing 1

Route of Administration

FOR INTRAVENOUS USE ONLY 11

• Serious adverse reactions including seizures and cardiac arrhythmias occur with inadvertent intrathecal administration
• Infuse no faster than 1 mL/minute to avoid hypotension 11

Alternative Routes

• Topical/mouthwash: For gingival/oral bleeding 10
• Nebulized: Shows promise for post-tonsillectomy hemorrhage and refractory epistaxis 7, 8
• Oral: For heavy menstrual bleeding 10

Practical Implementation

Pre-hospital administration: Consider giving first dose en route to hospital for trauma patients 2, 3. The STAAMP trial suggests repeated dosing up to 3 g total may be beneficial in hypotensive patients 1

Do not wait for laboratory results before administering TXA in trauma or major hemorrhage 3. The benefit of early administration outweighs the time lost waiting for coagulation studies.

Compatibility: Can be mixed with electrolyte solutions, carbohydrate solutions, amino acid solutions, and dextran. Heparin may be added. Do NOT mix with blood or penicillin-containing solutions 11